Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01774578 · ClinicalTrials.gov registry record · Phase 2
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by NewLink Genetics Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 135
- Enrollment target
NCT01774578: Clinical Trial Phase 2 study, sponsored by NewLink Genetics Corporation.
NCT01774578 is a Phase 2 study that was terminated before completion, run by NewLink Genetics Corporation. The registered enrollment target is 135 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01774578, a Phase 2 study, was terminated before completion, sponsored by NewLink Genetics Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 135 participants
- Enrollment target
Study Summary
The purpose of this study is to assess overall survival of anti-tumor immunization using HyperAcute®-Lung immunotherapy versus Docetaxel in patients with progressed or relapsed non-small cell lung cancer (NSCLC) that have been previously treated.
Primary Outcome
The primary objective in Phase IIB and Phase III is to assess overall survival of anti-tumor immunization using HyperAcute®-Lung (HAL) Immunotherapy versus docetaxel in patients with progressed or relapsed non-small cell lung cancer (NSCLC) that have been previously treated.
Interventions
- DRUG Docetaxel
- DRUG Pemetrexed
- DRUG Gemcitabine
- BIOLOGICAL HyperAcute®-Lung Immunotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2013-02 |
| Est. Completion | 2016-06-18 |
| Phase | Phase 2 |
Why NCT01774578 stopped before completion
NCT01774578 is an interventional study that assigns participants to a tested intervention. The registered 135 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 4 interventions - of which Docetaxel is the first listed.
NCT01774578 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01774578 about?
NCT01774578 is a clinical study titled "Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer". The purpose of this study is to assess overall survival of anti-tumor immunization using HyperAcute®-Lung immunotherapy versus Docetaxel in patients with progressed or relapsed non-small cell lung cancer (NSCLC) that have been previously treated.
What is the current status of trial NCT01774578?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 135 participants. The study started on 2013-02. Estimated completion is 2016-06-18.
What interventions are being tested in trial NCT01774578?
The interventions under investigation include: Docetaxel (DRUG), Pemetrexed (DRUG), Gemcitabine (DRUG), HyperAcute®-Lung Immunotherapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT01774578?
This trial is sponsored by NewLink Genetics Corporation, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01774578's enrollment target sits among peer trials
135 532nd of 2000 higher than 1,464 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00870129 · 135 participants · NA
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
- NCT03666000 · 135 participants · Phase 1
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT04891510 · 135 participants · NA
A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery
- NCT05121051 · 135 participants · Phase 2
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia